VPD-737 for Treatment of Chronic Pruritus

PHASE2CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

October 15, 2013

Primary Completion Date

December 2, 2014

Study Completion Date

December 2, 2014

Conditions
Chronic Pruritus
Interventions
DRUG

VPD-737

NK1 Receptor Antagonist

DRUG

Placebo

Trial Locations (25)

14623

Skin Search of Rochester, Inc., Rochester

19140

Temple University, Philadelphia

23233

WestEnd Dermatology Associates, Richmond

27262

Dermatology Consulting Services, High Point

30342

Advanced Medical Research, Inc., Atlanta

33180

The Center for Clinical and Cosmetic Research, Aventura

33431

Dermatology of Boca, Boca Raton

33486

Skin Care Research, Boca Raton

33609

Olympian Clinical Research, Tampa

46032

Shideler Clinical Research Center, Carmel

46168

The Indiana Clinical Trials Center, PC, Plainfield

48088

Grekin Skin Institue, Warren

55432

Minnesota Clinical Study Center, Fridley

68114

Quality Clinical Research Inc., Omaha

77056

Suzanne Bruce and Associates, P.A., Houston

78229

Dermatology Clinical Research Center of San Antonio, San Antonio

78660

Pfugerville Dermatology, Pflugerville

90717

Torrance Clinical Research Institute Inc., Lomita

94063

Stanford University, Medical Dermatology, Redwood City

94538

Center for Dermatology Clinical Research, Inc., Fremont

97035

Baker Allergy, Asthma and Dermatology Research Center, LLC, Lake Oswego

99204

Marycliff Allergy Specialist, Spokane

Unknown

UCSD Dermatology, San Diego

08009

Comprehensive Clinical Research, Berlin

07044

The Dermatology Group, P.C., Verona

All Listed Sponsors
lead

Vyne Therapeutics Inc.

INDUSTRY

NCT01951274 - VPD-737 for Treatment of Chronic Pruritus | Biotech Hunter | Biotech Hunter